読み込み中
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
終値時点
$92.34
−$1.47 · -1.57%
時間外
$92.3901
+$0.0501 · +0.05%
10月6日 17:04 ET
日中の時刻はETです。市場データは遅延する場合があります。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日中レンジ
現在 $92.34
52週レンジ
現在 $92.34
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
28
割高
センチメント
67
強気
リスク
58
やや高いリスク
モメンタム
76
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
日中レンジ
現在 $92.34
52週レンジ
現在 $92.34
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 2670.6万 USD | 2594.7万 USD | 1100.1万 USD | 871.1万 USD |
| 粗利益 | — | −2670.6万 USD | −2594.7万 USD | −1100.1万 USD | −871.1万 USD |
| 研究開発 | 1.82億 USD | 1.26億 USD | 2.06億 USD | 2.68億 USD | 2.17億 USD |
| 販売・一般管理 | 5201.5万 USD | 3404.8万 USD | 7102.3万 USD | 6278.7万 USD | 4100万 USD |
| 営業費用 | 2.34億 USD | 1.6億 USD | 2.51億 USD | 3.3億 USD | 2.58億 USD |
| 受取利息 | 451.7万 USD | 1114.8万 USD | 1673.3万 USD | 707.1万 USD | 29.8万 USD |
| 支払利息 | — | — | 1.3万 USD | 1.8万 USD | 2.2万 USD |
| 減価償却費と償却費 | 2632万 USD | 2670.6万 USD | 2594.7万 USD | 1100.1万 USD | 871.1万 USD |
| 営業利益 | −2.34億 USD | −1.87億 USD | −2.77億 USD | −3.41億 USD | −2.67億 USD |
| 純利益 | −2.3億 USD | −1.76億 USD | −2.6億 USD | −3.34億 USD | −2.67億 USD |
会社概要が更新されました 2026年10月6日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$98.40
上昇余地（6.56%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2022年2月23日 | 5:1 | — | — |
発効済み 2022年2月23日
5:1
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI1.19億1.18%100.95億 USD0.35%$150.9-3.39%
iShares Russell 2000 ETFIWM9666.66万0.12%790.26億 USD0.19%$281.37-0.71%
Vanguard Morningstar Total Stock Market ETFVTI4818.83万0.00%2.3兆 USD0.03%$382.54+0.51%
iShares Biotechnology ETFIBB4126.18万0.40%105.49億 USD0.44%$203.1-2.34%
iShares Russell 2000 Growth ETFIWO3462.86万0.24%142.94億 USD0.24%$360.53-0.90%
Schwab U.S. Small-Cap ETFSCHA1965.7万0.09%220.83億 USD0.03%$33.10-0.42%
Vanguard Extended Market ETFVXF1784.69万0.02%954億 USD0.05%$237.2+0.02%
Fidelity Enhanced Small Cap ETFFESM1432.77万0.22%64.9億 USD0.28%$45.74-0.57%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
